Olin Corporation (NYSE:OLN) announced today it now expects third quarter 2022 adjusted EBITDA to be in the range of $530 – $550 million. On July 28, 2022, we previously guided third quarter 2022 adjusted EBITDA to decline approximately 15% from our second quarter 2022 adjusted EBITDA of $727 million.
Pfizer’s Elderly Vaccine Efficacy Drops Slightly After 18 Months, New Clinical Trials Reveal – CDC Advisory Panel Set To Vote Today On Recommended Use Of RSV Shots
Pfizer Inc's (NYSE: PFE) vaccine for elderly 60 and above was slightly less effective after 18 months, according to the company's clinical trial
